Butidrine

This classification denotes an adrenergic antagonist with the molecular formula C16H25NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N2S0PKP5L5, chemically known as 5,6,7,8-tetrahydro-alpha-(((1-methylpropyl)amino)methyl)-2-naphthalenemethanol hydrochloride but generally known as butidrine, which bears US NIH Compound Identifier 15176. Butidrine most often comes in base and hydrochloride forms. European Medicines Agency schedules Butidrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06016MIG. The term BUTIDRINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). BUTIDRINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule butidrine under HS 29221980 and SITC 51461. As of Q4 2014, BUTIDRINE remains the US FDA Preferred Term for this commodity. Butidrine bears US NLM identifiers UMLS ID C2698577 and NCI Concept Code C79710. SMILES: CL.OC(C[NH2]C(CC)C)C1CC2CCCCC2CC1.